Drug Profile
Research programme: hedgehog pathway inhibitors - IMPACT Therapeutics
Alternative Names: IMP 5364Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator IMPACT Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Hedgehog cell-signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Cancer in China (PO)
- 28 Apr 2020 Preclinical development is ongoing in Cancer in China (PO) (IMPACT Therapeutics pipeline, April 2020)
- 28 Apr 2020 IMPACT Therapeutics files for patent protection for its Hedgehog pathway inhibitors (IMPACT Therapeutics pipeline, April 2020)